Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 132

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 132
---
 three months ended September 30, 2025. The Company recorded a $1.3 million expense and a $0.1 million expense due to the change in the fair value of the contingent consideration liabilities for the USWM milestones for the three and nine months ended September 30, 2024, respectively. The change in fair value of contingent consideration was primarily due to accretion to the full milestone payment amount with the achievement of the milestones. ONAPGO was approved by the FDA in February 2025 and was launched in April 2025. The Company recorded the following changes in fair value of the contingent consideration liabilities for the Adamas CVRs:•The Company recorded a $2.3 million gain and a $6.6 million gain due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three and nine months ended September 30, 2024, respectively. The change in fair value of contingent consideration was primarily due to passage of time. The Company recorded the following changes in the fair value of contingent consideration liability for the Sage CVRs:•The Company recorded a contingent consideration liability of $11.4 million at Sage Closing Date. No change in fair value was recorded during the three and nine months ended September 30, 2025 given the proximity of the Sage Acquisition to the reporting period end date.

8.    Goodwill and Intangible Assets, Net

GoodwillThe following table sets forth the gross carrying amounts of goodwill (dollars in thousands):Balance as of December 31, 2024$117,019 Goodwill from Sage Acquisition2,061 Balance as of September 30, 2025 (unaudited)$119,080 The increase in goodwill is from the Sage Acquisition. See Note 3, Sage Acquisition, for further discussion. 

25

Intangible Assets, NetThe following table sets forth the gross carrying amounts and related accumulated amortization of intangible assets (dollars in thousands):September 30, 2025December 31, 2024(unaudited)Remaining WeightedAverage Life (Years)Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, NetAcquired in-process research and development$— $— $— $124,000 $— $124,000 Intangible assets subject to amortization:Acquired developed technology and